United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - loratadine - tablet - 10mg

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - atenolol - film coated tablet - 50 milligram - beta blocking agents, selective

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - atenolol - film coated tablet - 25 milligram - beta blocking agents, selective

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - atenolol - film coated tablet - 100 milligram - beta blocking agents, selective

European Union - English - EMA (European Medicines Agency)

actavis group ptc ehf    - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - metformin hydrochloride - modified-release tablet - 1gram

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - ibuprofen - coated tablet - ibuprofen 200 mg - antiinflammatory and antirheumatic products

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - ibuprofen - coated tablet - ibuprofen 400 mg - antiinflammatory and antirheumatic products

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - ibuprofen - coated tablet - ibuprofen 600 mg - antiinflammatory and antirheumatic products

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - ibuprofen - coated tablet - ibuprofen 800 mg - antiinflammatory and antirheumatic products